SCHEMBL3447975

SCHEMBL3447975

O=C(O)/C=C/c1cccc(-c2cnc(Nc3ccc(F)c(F)c3)nc2N2CCOCC2)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PIM2 Q9P1W9 2/20 0.50
▸ BTK Q06187 5/20 0.45
▸ NPC1 O15118 1/20 0.42
▸ RAB9A P51151 1/20 0.42
▸ SMN1; SMN2 Q16637 1/20 0.42
▸ MTOR P42345 1/20 0.41
▸ MAPK9 P45984 1/20 0.41
▸ MAPK10 P53779 1/20 0.41
▸ JAK2 O60674 2/20 0.41
▸ MAP3K7 O43318 2/20 0.40
▸ IRAK4 Q9NWZ3 2/20 0.40
▸ CCNT1 O60563 1/20 0.40
▸ CCNE1 P24864 1/20 0.40
▸ CDK2 P24941 1/20 0.40
▸ CDK9 P50750 1/20 0.40
▸ JAK3 P52333 2/20 0.40
▸ SYK P43405 2/20 0.40
▸ JAK1 P23458 1/20 0.40
▸ TYK2 P29597 1/20 0.40
▸ STAT6 P42226 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3447978 1.00 PIM2 (0.50) PIM2BTKNPC1RAB9ASMN1; SMN2
SCHEMBL3447480 0.93 PIM2 (0.48) PIM2BTKNPC1RAB9ASMN1; SMN2
SCHEMBL13311434 0.93 PIM2 (0.48) PIM2BTKNPC1RAB9ASMN1; SMN2
SCHEMBL13311469 0.93 PIM2 (0.48) PIM2BTKNPC1RAB9ASMN1; SMN2
SCHEMBL3447477 0.93 PIM2 (0.48) PIM2BTKNPC1RAB9ASMN1; SMN2
SCHEMBL3449439 0.92 PIM2 (0.47) PIM2BTKNPC1RAB9ASMN1; SMN2
SCHEMBL3449446 0.92 PIM2 (0.47) PIM2BTKNPC1RAB9ASMN1; SMN2
SCHEMBL13311437 0.92 PIM2 (0.51) PIM2BTKNPC1RAB9ASMN1; SMN2
SCHEMBL13311394 0.91 PIM2 (0.47) PIM2BTKNPC1RAB9ASMN1; SMN2
SCHEMBL13311461 0.91 NPC1 (0.47) PIM2BTKNPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB 2010-06-03 — — US disclosed
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB 2010-06-03 — — US disclosed
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB 2010-06-03 — — US disclosed
WO-2010038081-A2 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB (SE) 2010-04-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF SDHA, SDHB, UROD PIM2 3060/4885BTK 1019/4885NPC1 603/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback